Hamed Hamishehkar
1, Maryam Pourtahmaseb
2,3, Afshin Babazadeh
4,5, Shohreh Alipour
3,6*1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Pharmacy Faculty, Shiraz University of Medical Sciences, Shiraz, Iran.
4 Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
5 Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.
6 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
Background: Respiratory fungal diseases therapy is still facing challenges as
a result of increasing autoimmune disorders, cancers, and immunosuppressive
medication usage. Fluconazole is a wide spectrum antifungal agent and is still
used successfully in the treatment of opportunistic infections in combination
with other antifungal agents. Since, the treatment of respiratory fungal
diseases requires prolonged hospitalization; it may increase the chances of
other opportunistic infections. Considering the reported drug resistance and
adverse effects of systemic administration, it appears that localized pulmonary
antifungal therapy may be a suitable alternative route. According to the
reported suitable inhalation properties of spray dried powders; spray drying
technique was used to prepare fluconazole powders.
Methods: Different
spray drying parameters such as inlet temperature, pump rate, aspiration%,
solvent type, as well as fluconazole concentration were evaluated for powder
production. The optimized formulations were characterized using scanning
electron microscopy (SEM), x-ray diffraction (XRD), differential scanning
calorimetry (DSC) and aerodynamic parameters.
Results: All selected formulations showed a smooth surface with similar
mass median aerodynamic diameter (MMAD) in a respiratory acceptable range.
While optimized powder showed a lower geometric standard deviation (GSD) of 1.5
with higher fine particle fraction (FPF) of 26% and almost complete deposition
recovery of 97%.
Conclusion: Based on in vitro
characterization results, it appears that spray drying is an appropriate and
cost-effective technique for the production of inhalable fluconazole powder. It
is characterized by a narrower size distribution and delivers a higher dose
which may be more cost effective for mass production.